Detailed Notes CHAPTER 10 BIOTECHNOLOGY AND ITS APPLICATIONS

CHAPTER 10 BIOTECHNOLOGY AND ITS APPLICATIONS

Introduction 

1. Biotechnology’s Scope:

   • Large-scale Production: Biotechnology focuses on producing substances like biopharmaceuticals (e.g., insulin) and biologicals (e.g., vaccines) in large quantities.
   • Genetically Modified Organisms: It involves using genetically modified microbes (bacteria, yeast), fungi, plants, and animals to create these substances.

2. Applications of Biotechnology:

   • Therapeutics: Developing treatments and drugs for diseases like cancer, diabetes, and genetic disorders using biotechnological methods.
   • Diagnostics: Creating tools and tests based on biotechnology to detect diseases accurately and monitor health conditions.
   • Genetically Modified Crops: Modifying crop plants to have desirable traits such as resistance to pests, tolerance to herbicides, or improved nutritional content.
   • Processed Food: Using biotechnology in food production to enhance flavor, shelf life, and nutritional value.
   • Bioremediation: Using biological agents to clean up pollutants in soil, water, and air.
   • Waste Treatment: Applying biological processes to treat waste materials, such as converting organic waste into compost or biofuels.
   • Energy Production: Using biological processes like fermentation to produce biofuels such as ethanol or biodiesel.

3. Critical Research Areas in Biotechnology:

   • Improved Organisms: Research focuses on developing better catalysts, which can be microbes (like bacteria) or enzymes, to perform specific tasks efficiently.
   • Optimal Conditions: Scientists engineer environments (temperature, pH, nutrients) to create the best conditions for these catalysts to work effectively.
   • Downstream Processing: Developing methods to purify and separate the desired products (such as proteins or organic compounds) from the rest of the biological material.

4. Improvements in Food Production and Health:

   • Food Production: Biotechnology has led to the development of crops that are more resistant to pests and diseases, resulting in higher yields and more sustainable agriculture.
   • Health: It has revolutionized healthcare by providing advanced therapies such as gene editing, personalized medicine, and biopharmaceuticals produced through biotechnological processes.

10.1 BIOTECHNOLOGICAL APPLICATIONS IN AGRICULTURE

1. Options for Increasing Food Production:

   • Agro-chemical based agriculture: Relies on fertilizers and pesticides for increased yield.
   • Organic agriculture: Focuses on natural methods without synthetic chemicals.
   • Genetically engineered crop-based agriculture: Involves modifying crop genetics for desired traits.

2. Challenges Post Green Revolution:

   • Despite the Green Revolution’s success in tripling food supply, it wasn’t enough to meet growing population needs.
   • Increased yields were due to improved crop varieties and management practices, including agrochemicals.
   • Agrochemicals can be expensive for farmers in developing countries, limiting yield increases.

3. Tissue Culture as a Solution:

   • Definition: Tissue culture is the process of growing whole plants from small plant parts (explants) in a sterile, nutrient-rich medium.
   • Totipotency: Explants can regenerate into whole plants under controlled conditions, offering rapid propagation of plants.
   • Micro-propagation: Producing thousands of genetically identical plants (somaclones) from a single parent plant.
   • Benefits: Enables rapid production of disease-free plants and genetic clones for commercial agriculture.

4. Genetically Modified Organisms (GMOs) in Agriculture:

   • Definition: Organisms with altered genes, created through genetic engineering.
   • Benefits of GM Plants:
     • Increased tolerance to environmental stresses like cold, drought, and heat.
     • Reduced need for chemical pesticides due to built-in pest resistance.
     • Reduced post-harvest losses and improved nutrient utilization.
     • Enhanced nutritional value (e.g., golden rice with vitamin A enrichment).
     • Creation of tailor-made plants for industrial resources like starches and fuels.

5. Examples of Biotechnological Applications:

   • Bt Toxin in Plants: Bt toxin genes from Bacillus thuringiensis are inserted into crop plants like cotton, corn, and soybeans to confer insect resistance without chemical pesticides.
   • Pest Resistance via RNA Interference (RNAi): Using RNAi to silence specific genes in pests like nematodes, preventing infestations in crops.

10.2 BIOTECHNOLOGICAL APPLICATIONS IN MEDICINE

1. Impact of Recombinant DNA Technology:

   • Mass Production: Recombinant DNA technology enables large-scale production of therapeutic drugs.
   • Safety and Effectiveness: These drugs are safer and more effective compared to products isolated from non-human sources.
   • Immunological Responses: Recombinant therapeutics are less likely to induce unwanted immunological responses in patients.

2. Approved Recombinant Therapeutics:

   • Worldwide: Approximately 30 recombinant therapeutics have been approved for human use globally.
   • India: In India, 12 of these recombinant therapeutics are currently being marketed.

10.2.1 Genetically Engineered Insulin

1. Challenges with Non-Human Insulin:

   • Availability: If enough human insulin is not available, diabetic patients might have to rely on insulin isolated from other animals.
   • Effectiveness and Immune Response: Insulin from other animals may not be as effective as human insulin and can elicit an immune response in the human body, leading to allergies or reactions.

2. Advantages of Genetically Engineered Insulin:

   • Simplified Production: Using bacteria capable of producing human insulin simplifies the production process.
   • Large-Scale Production: Bacteria can be grown in large quantities to produce the required amount of insulin.

3. Oral Administration of Insulin:

   • Feasibility: Insulin cannot be orally administered to diabetic people because it gets broken down in the digestive system before it can be absorbed into the bloodstream.
   • Insulin Structure: Insulin consists of two short polypeptide chains (A and B) linked by disulfide bridges, and it is synthesized as a pro-hormone with an additional C peptide, which is removed during maturation.

4. Production of Genetically Engineered Insulin:

   • rDNA Techniques: Recombinant DNA technology is used to produce human insulin.
   • E. coli Expression System: DNA sequences corresponding to insulin chains A and B are introduced into plasmids of E. coli bacteria.
   • Separate Production: Chains A and B are produced separately within the bacteria and then combined to form mature human insulin by creating disulfide bonds.

10.2.2 Gene Therapy

1. Gene Therapy for Hereditary Diseases:

   • Purpose: Gene therapy aims to correct gene defects that cause hereditary diseases.
   • Method: It involves inserting genes into a person’s cells and tissues to treat the disease by compensating for the non-functional gene.

2. Clinical Application:

   • First Clinical Gene Therapy: The first clinical gene therapy was administered in 1990 to a 4-year-old girl with adenosine deaminase (ADA) deficiency.
   • ADA Deficiency: ADA deficiency affects the immune system due to the deletion of the gene responsible for adenosine deaminase enzyme production.

3. Treatment Approaches for ADA Deficiency:

   • Bone Marrow Transplantation: Some cases of ADA deficiency can be cured by bone marrow transplantation.
   • Enzyme Replacement Therapy: Others can be treated with enzyme replacement therapy, where functional ADA is injected into the patient.
   • Limitations: These approaches are not always completely curative and may require periodic treatments.

4. Gene Therapy Process for ADA Deficiency:

   • Cell Culturing: Lymphocytes (immune cells) are taken from the patient’s blood and grown in a culture outside the body.
   • Gene Insertion: A functional ADA gene is introduced into these lymphocytes using a retroviral vector.
   • Return to Patient: The genetically engineered lymphocytes are then returned to the patient.
   • Limitations of Current Approach: The patient may still require periodic infusion of genetically engineered lymphocytes because these cells are not immortal.

5. Potential Long-Term Cure:

   • Embryonic Stage Gene Insertion: Introducing the functional ADA gene into cells at early embryonic stages could potentially provide a permanent cure for ADA deficiency.